Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study | Zendy

Uwe Platzbecker | Zendy; Katharina S. Götze | Zendy; Philipp Kiewe | Zendy; Ulrich Germing | Zendy; Karin Mayer | Zendy; Markus P. Radsak | Zendy; Thomas Wolff | Zendy; Jöerg Chromik | Zendy; Katja Sockel | Zendy; Uta Oelschlägel | Zendy; Detlef Haase | Zendy; Thomas Illmer | Zendy; Haifa Kathrin AlAli | Zendy; Gerda Silling | Zendy; Joseph G. Reynolds | Zendy; Xiaosha Zhang | Zendy; Kenneth M. Attie | Zendy; Jeevan K. Shetty | Zendy; Aristoteles Giagounidis | Zendy

Open Access

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

Author(s) -

Uwe Platzbecker,

Katharina S. Götze,

Philipp Kiewe,

Ulrich Germing,

Karin Mayer,

Markus P. Radsak,

Thomas Wolff,

Jöerg Chromik,

Katja Sockel,

Uta Oelschlägel,

Detlef Haase,

Thomas Illmer,

Haifa Kathrin AlAli,

Gerda Silling,

Joseph G. Reynolds,

Xiaosha Zhang,

Kenneth M. Attie,

Jeevan K. Shetty,

Aristoteles Giagounidis

Publication year - 2022

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.21.02476

Subject(s) - medicine , myelodysplastic syndromes , clinical endpoint , international prognostic scoring system , anemia , erythropoiesis , phases of clinical research , ruxolitinib , bone marrow , clinical trial , myelofibrosis , gastroenterology , oncology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research